Breaking News Instant updates and real-time market news.

GILD

Gilead

$81.82

1.03 (1.27%)

, ABBV

AbbVie

09:44
02/15/18
02/15
09:44
02/15/18
09:44

Lawmakers to push for hep C drug patents being taken, Capitol Forum says

Representative Ro Khanna and 10 other Congress members plan to send a letter urging HHS Secretary Alex Azar to use his legal authority to take patents for hepatitis C virus drugs, according to The Capitol Forum, citing word from Khanna's office. Makers of hep C drugs include Gilead (GILD) and AbbVie (ABBV). Reference Link

GILD

Gilead

$81.82

1.03 (1.27%)

ABBV

AbbVie

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

GILD Gilead
$81.82

1.03 (1.27%)

01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/07/18
SBSH
02/07/18
NO CHANGE
Target $105
SBSH
Buy
Gilead should be bought ahead of pipeline catalysts, says Citi
Citi analyst Robyn Karnauskas raised her price target for Gilead Sciences to $105 from $103 following last night's Q4 results. The analyst recommends buying the stock ahead of pipeline catalysts and keeps a Buy rating on the name. The base business seems to be stabilizing while gene therapy could be a potential growth area, Karnauskas tells investors in a post-earnings research note.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
02/09/18
WELS
02/09/18
NO CHANGE
WELS
Outperform
Gilead should be bought on patent challenge weakness, says Wells Fargo
Wells Fargo analyst Jim Birchenough recommends buying Gilead Sciences on weakness following a patent infringement lawsuit against recently approved single tablet regimen Biktarvy for HIV. The analyst believes that Biktarvy patents will hold up to challenge and that the lawsuit will not impact launch or longer term value creation. He remains confident in Gilead's growth beyond "trough earnings" in 2018 and keeps an Outperform rating on the stock.
ABBV AbbVie

01/30/18
01/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Underperform from Market Perform by analyst Alex Arfaei, who said the risk/reward has "meaningfully changed" after the rise in the stock price, adding that the new focus on fundamentals beyond the benefits of tax reform suggests "significant price erosion in immunology driven by interchangeable biosimilar anti-TNFs, and lower effectiveness of the 'Rebate Trap' to block access to cheap biosimilars". 2. iRobot (IRBT) downgraded to Neutral from Buy at Sidoti by analyst Frank Camma, who cited valuation as shares approach his $98 price target. 3. Horizon Global (HZN) downgraded to Market Perform from Outperform at BMO Capital by analyst Gerrick Johnson, who said that while he still sees "strong demand in key end markets," operation execution, rising input costs, and high debt levels are concerning. The analyst added that the company may have "lost the faith of investors" after a 30% drop in the stock price following the guidance cut. 4. Yum! Brands (YUM) downgraded to Neutral from Buy at Nomura Instinet by analyst Mark Kalinowshi, who cited valuation and concerns a possible 2018 slowdown in U.S. same-store-sales. 5. Alaska Air (ALK) downgraded to Underweight from Neutral at JPMorgan by analyst Jamie Baker, who noted that the airline is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." The analyst also downgraded Southwest (LUV) to Neutral from Overweight, and said he believes better relative value exists elsewhere in the Airlines sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
ARGS
02/02/18
NO CHANGE
Target $145
ARGS
Buy
AbbVie price target raised to $145 from $120 at Argus
Argus analyst David Toung raised his price target on AbbVie to $145 and kept his Buy rating after a "solid" Q4 earnings report that also included a substantial boost from lower tax rates. Toung says AbbVie is likely to submit more applications for new products and expanded indications of existing drugs this year as it develops new growth drivers such as Imbruvica and Mavyret to complement the current large contribution from Humira.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

, SPX

S&P 500

19:25
02/22/18
02/22
19:25
02/22/18
19:25
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Treasury Sec.: Trump…

SPY

SPDR S&P 500 ETF Trust

$270.40

0.35 (0.13%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMAB

OMA Airports

$41.47

0.33 (0.80%)

19:10
02/22/18
02/22
19:10
02/22/18
19:10
Hot Stocks
OMA Airports reports Q4 passenger traffic up 1.8% »

Total terminal passenger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIV

Aimco

$38.28

0.28 (0.74%)

19:05
02/22/18
02/22
19:05
02/22/18
19:05
Hot Stocks
Aimco acquires Bent Tree apartment community for $160M »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$292.99

0.27 (0.09%)

18:50
02/22/18
02/22
18:50
02/22/18
18:50
Upgrade
TransDigm rating change  »

TransDigm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.60

-0.16 (-4.26%)

18:49
02/22/18
02/22
18:49
02/22/18
18:49
Hot Stocks
Kadmon updates 'positive' results from Phase 2 study of KD025 in cGVHD »

Kadmon announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASR

Asur

$182.83

1.49 (0.82%)

18:47
02/22/18
02/22
18:47
02/22/18
18:47
Hot Stocks
Asur reports Q4 passenger traffic down 4% »

ASUR's total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.27

-0.83 (-1.51%)

18:45
02/22/18
02/22
18:45
02/22/18
18:45
Periodicals
Judge criticizes U.S. Bancorp deal to sidestep prosecution, Bloomberg reports »

U.S. District Judge Lewis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 30

    May

KZIA

Kazia Therapeutics

$4.99

0.43 (9.43%)

18:36
02/22/18
02/22
18:36
02/22/18
18:36
Hot Stocks
Kazia granted orphan status for glioblastoma treatment »

The FDA granted Kazia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:29
02/22/18
02/22
18:29
02/22/18
18:29
Hot Stocks
Obsidian Energy reports 126% reserve replacement of 2017 production »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBE

Obsidian Energy

$0.98

0.0183 (1.91%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Hot Stocks
Obsidian Energy names Jay Thornton chairman of the board »

Obsidian Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:27
02/22/18
02/22
18:27
02/22/18
18:27
Earnings
SSR Mining reports Q4 adjusted EPS 2c, consensus 7c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SSRM

SSR Mining

$8.33

0.06 (0.73%)

18:21
02/22/18
02/22
18:21
02/22/18
18:21
Hot Stocks
SSR Mining sees 2018 gold production 340K gold equivalent ounces »

SSR Mining expect to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

IVC

Invacare

$17.97

-0.28 (-1.53%)

18:20
02/22/18
02/22
18:20
02/22/18
18:20
Hot Stocks
Invacare names Kathleen Leneghan as CFO, effective immediately »

Invacare announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SHCAY

Sharp

$8.21

-0.025 (-0.30%)

18:18
02/22/18
02/22
18:18
02/22/18
18:18
Periodicals
Sharp drops legal action against Hisense over TV brands, Nikkei reports »

Sharp has dropped legal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$40.91

0.35 (0.86%)

18:17
02/22/18
02/22
18:17
02/22/18
18:17
Periodicals
GM seeks South Korean aid to bolster local unit, Nikkei Asian Review reports »

General Motors is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:14
02/22/18
02/22
18:14
02/22/18
18:14
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

TRTN

Triton International

$28.16

-0.4 (-1.40%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Triton International reports Q4 adjusted EPS 85c, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SJI

South Jersey Industries

$26.34

0.23 (0.88%)

18:13
02/22/18
02/22
18:13
02/22/18
18:13
Earnings
Breaking Earnings news story on South Jersey Industries »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

PAA

Plains All American

$20.97

-0.43 (-2.01%)

18:09
02/22/18
02/22
18:09
02/22/18
18:09
Hot Stocks
Plains All American's Cactus II pipeline fully committed »

Plains All American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 07

    Mar

STX

Seagate

$51.36

-0.08 (-0.16%)

18:03
02/22/18
02/22
18:03
02/22/18
18:03
Initiation
Seagate initiated  »

Seagate resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WDC

Western Digital

$85.53

-0.14 (-0.16%)

18:01
02/22/18
02/22
18:01
02/22/18
18:01
Initiation
Western Digital initiated  »

Western Digital resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$21.39

0.22 (1.04%)

17:56
02/22/18
02/22
17:56
02/22/18
17:56
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 24

    Apr

  • 30

    May

BKD

Brookdale Senior Living

$7.18

-1.72 (-19.33%)

17:52
02/22/18
02/22
17:52
02/22/18
17:52
Downgrade
Brookdale Senior Living rating change  »

Brookdale Senior Living…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AQMS

Aqua Metals

$2.62

-0.25 (-8.71%)

17:52
02/22/18
02/22
17:52
02/22/18
17:52
Hot Stocks
Philotimo Fund reports 6.5% stake in Aqua Metals »

Philotimo Fund purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$32.31

-0.1271 (-0.39%)

17:47
02/22/18
02/22
17:47
02/22/18
17:47
Earnings
Pembina Pipeline reports Q4 adjusted EPS 99c, consensus 37c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.